Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) superfamilies, is a candidate for cancer therapy due to its ability to selectively trigger apoptosis in tumor cells but not normal cells (3-5). This evidence concerns the gene TNFSF10 and neoplasm.